Xeris Biopharma Holdings, Inc.XERSNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 90% recommend buying.

Consensus Rating

Buy

10 analysts·Moderate coverage

90%

Rating Distribution

Strong Buy

00%

Buy

990%

Hold

110%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 83% higher.

Bear Case

$9.00

+22%

Consensus

$13.50

+83%

Bull Case

$18.00

+145%

Price Range10 analysts

Low

Consensus

High

$9.00

$18.00

Current Target

Current Price

$7.36

Upside to Target

$6.14

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.18(4 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+18.29%

EPS+104.07%

FY2028

Rev+14.03%

EPS+72.66%

FY2029

Rev+15.05%

EPS+25.68%

Earnings Surprises

Beat rate:67%(8/12 quarters)

Avg surprise:+14.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 8, 2025Barclays

Xeris Biopharma initiated with an Overweight at Barclays

Target:$9.00

+28.8%from $6.99

Oct 29, 2025Oppenheimer

Xeris Biopharma price target raised to $18 from $8 at Oppenheimer

Target:$18.00

+80.5%from $9.97

Mar 7, 2025Piper Sandler

Xeris Biopharma price target raised to $4 from $3 at Piper Sandler

Target:$4.00

-5.7%from $4.24

Nov 11, 2024H.C. Wainwright

Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright

Target:$6.60

+103.4%from $3.25

Oct 23, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)

Target:$5.00

+65.6%from $3.02

May 10, 2024Piper Sandler

Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler

Target:$3.00

+62.4%from $1.85

Apr 28, 2022Craig-Hallum

Craig-Hallum Initiates Coverage On Xeris Biopharma Holdings with Buy Rating, Announces Price Target of $6.5

Target:$6.50

+179.0%from $2.33

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance